Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of single rising oral doses of vicadrostat in healthy Chinese and Japanese males
NCT03206632Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vicadrostat in chronic kidney disease (CKD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of subjects with adverse reactions up to 336 hours. Started Jul 2017; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03206632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206632.